With enrollment closed, Pro-Pharmaceuticals is focused on finishing the treatment and evaluation of patients in the trial. The trial is expected to evaluate up to a total of 40 patients.
Davanat is a proprietary polysaccharide that enables the targeted delivery of chemotherapy drugs to protein receptors (lectins) that are unique to cancer cells.
Pro-Pharmaceuticals is a drug development company commercializing a new generation of anticancer treatments using carbohydrate compounds to glyco-upgrade the safety and efficacy of FDA-approved chemotherapy drugs.
The company has been conducting pre-clinical studies for irinotecan, doxorubicin, oxaliplatin, paclitaxel, cyclophosphamide and cisplatin both in combination with Davanat and other polysaccharide compounds. Results so far show that Davanat exhibits a broad spectrum of activity with the tested drugs.